Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Rises By 388.6%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 2,795 shares, a growth of 388.6% from the February 12th total of 572 shares. Based on an average trading volume of 5,925 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.3% of the company’s stock are sold short. Currently, 0.3% of the company’s stock are sold short. Based on an average trading volume of 5,925 shares, the days-to-cover ratio is presently 0.5 days.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of NASDAQ:GNOM traded down $0.88 during midday trading on Tuesday, hitting $45.33. 6,750 shares of the stock were exchanged, compared to its average volume of 9,742. The company has a market capitalization of $49.41 million, a PE ratio of -19.37 and a beta of 1.22. Global X Genomics & Biotechnology ETF has a 52-week low of $27.20 and a 52-week high of $51.42. The business’s fifty day simple moving average is $47.14 and its two-hundred day simple moving average is $44.01.

Global X Genomics & Biotechnology ETF Dividend Announcement

The company also recently announced a dividend, which was paid on Wednesday, January 7th. Shareholders of record on Tuesday, December 30th were given a $0.5912 dividend. This represents a yield of 259.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Global X Genomics & Biotechnology ETF’s dividend payout ratio is presently -26.50%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Institutional investors have recently made changes to their positions in the company. Creative Financial Designs Inc. ADV increased its holdings in Global X Genomics & Biotechnology ETF by 4.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after buying an additional 481 shares during the last quarter. IFP Advisors Inc raised its position in Global X Genomics & Biotechnology ETF by 20.8% during the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after acquiring an additional 489 shares in the last quarter. Atria Investments Inc lifted its stake in Global X Genomics & Biotechnology ETF by 12.6% in the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock valued at $156,000 after acquiring an additional 2,073 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after acquiring an additional 4,615 shares during the last quarter. Finally, Jane Street Group LLC grew its position in Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after acquiring an additional 10,308 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.